Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Follow-on biologics: data exclusivity and the balance between innovation and competition

Nature Reviews Drug Discovery volume 7, pages 479–488 (2008)Cite this article

Abstract

Legislation to create a regulatory pathway for follow-on biologics is currently being considered by the United States Congress. A critical issue in this respect is the period of data exclusivity for innovator companies before a follow-on competitor can rely in part on data obtained for an original biologic for an abbreviated approval. Given the nature of patents on biologics, the period of data exclusivity is anticipated to have a key role in determining how quickly follow-on competitors emerge, and consequently also on the time available for originator companies to recoup their investment. With this issue in mind, this article discusses factors influencing return on investment on biologic research and development. A break-even analysis for a representative portfolio of biologics provides support for a substantial data exclusivity period.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Clinical development and approval times for chemical drugs and biologics.
Figure 2: Development times for new protein therapeutics.
Figure 3: Cumulative present value of cash flow versus R&D investment for the mean new chemical drug introduced between 1980 and 1984.
Figure 4: Model portfolio based on sales distribution for established biological products.
Figure 5: Life-cycle profile for the mean product in the model biologic portfolio.
Figure 6: Break-even lifetimes for new biological entities.

References

  1. Mossinghoff, G. J. Overview of the Hatch–Waxman Act and its impact on the drug development process. Food Drug Law J. 54, 187–194 (1999).

    CAS  PubMed  Google Scholar 

  2. Grabowski, H. G., Cockburn, I. & Long, G. The market for follow-on biologics: how will it evolve? Health Aff. 25, 1291–1301 (2006).

    Article  Google Scholar 

  3. Grabowski, H. G., Ridley, D. B. & Schulman, K. A. Entry and competition in generic biologics. Manag. Decis. Econ. 28, 439–451 (2007).

    Article  Google Scholar 

  4. Mansfield, E. Patents and innovation: an empirical study. Manag. Sci. 32, 173–181 (1986).

    Article  Google Scholar 

  5. Cohen, W. M., Nelson, R. R. & Walsh, J. Protecting Their Intellectual Assets: Appropriability Conditions and Why U. S. Manufacturing Firms Patent (Or Not). National Bureau of Economic Research (NBER) Working Paper 7552. NBER web site [online], (2000).

    Google Scholar 

  6. Scherer, F. M. The Political Economy of Patent Policy Reform in the United States. John F. Kennedy School of Government (KSG), Harvard University Working Paper RWP07-042. KSG web site [online], (2007).

    Google Scholar 

  7. Verheugen, G. Future Post G-10 Pharmaceutical Strategy. Speech at the Annual Meeting of European Federation of Pharmaceutical Industry and Association. European Union web site [online], (2005).

    Google Scholar 

  8. Towse, A. Developing the Idea of Transferable Intellectual Property Rights (TIPP) to Incentivise R&D in Drugs and Vaccines for Neglected Diseases Appendix 1, 22–24 (Office of Health Economics, London, 2004).

    Google Scholar 

  9. Calfee, J. E. & Barfield, C. Biotechnology and the Patent System: Balancing Innovation and Property Rights (AEI, Washington, DC, 2007).

    Google Scholar 

  10. Manheim, B. S. & Granahan, P. & Dow, K. J. 'Follow-on biologics': ensuring continued innovation in the biotech industry. Health Aff. 25, 394–404 (2006).

    Article  Google Scholar 

  11. Burk, D. L. & Lemley, M. A. Is patent law technology specific? Berkeley Technol. Law J. 17, 1182 (2002).

    Google Scholar 

  12. Grabowski, H. G. Are the economics of pharmaceutical research and development changing: productivity, patents and potential pressures. PharmacoEconomics 22 (Suppl. 2), 15–24 (2004).

    Article  Google Scholar 

  13. Berndt, E. R., Mortimer, R., Bhattacharjya, A., Parece, A. & Tuttle, E. Authorized generic drugs, price competition and consumers' welfare. Health Aff. 26, 790–799 (2007).

    Article  Google Scholar 

  14. Nordhaus, W. Invention, Growth and Welfare: A Theoretical Treatment of Technological Change 1–168 (Cambridge MIT Press, Cambridge, Masssachussets, 1969).

    Google Scholar 

  15. Scherer, F. M. & Ross, D. Industrial Market Structure and Economic Performance 3rd edn 1–713 (Houghton Miffen, Boston, Massachussets, 1990).

    Google Scholar 

  16. DiMasi, J. A. & Grabowski, H. G. The cost of biopharmaceutical R&D: is biotech different? Manag. Decis. Econ. 28, 469–479 (2007).

    Article  Google Scholar 

  17. PAREXEL. in PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2004/2005 (ed. Mathieu, M.) 168 (PAREXEL, Waltham, Massachussetts, 2004).

  18. Berndt, E. R., Gottschalk, A. H., Philipson, T. J. & Strobeck, M. W. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates. Nature Rev. Drug Discov. 4, 545–554 (2005).

    Article  CAS  Google Scholar 

  19. Grossmann, M. Entrepreneurship in Biotechnology. Managing for Growth from Start-Up to Initial Public Offering 1–323 (Physica-Verlag, New York, 2003).

    Google Scholar 

  20. Myers, S. C. & Shyum-Sunder, L. in Competitive Strategies in the Pharmaceutical Industry. (ed. Helms, R. B.) 208–237 (AEI, Washington, DC, 1996).

    Google Scholar 

  21. DiMasi, J. A., Hansen, R. N. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 141–185 (2003).

    Article  Google Scholar 

  22. Grabowski, H. G. Patents and new product development in the pharmaceutical and biotechnology industries. Georgetown Public Policy Rev. 8, 7–24 (2003).

    Google Scholar 

  23. Grabowski, H. G. in Science and Cents. Exploring the Economics of Biotechnology (eds Duca, J. V. & Yucel, M. K.) 87–104 (Federal Reserve Bank of Dallas, Texas, 2003).

    Google Scholar 

  24. Scherer, F. M. & Harhoff, D. Technology policy for a world of skew — distributed outcomes. Res. Policy 29, 559–566 (2000).

    Article  Google Scholar 

  25. Lichtenberg, F. The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982–2001. Int. J. Health Care Finance Econ. 5, 47–73 (2001).

    Article  Google Scholar 

  26. Nordhaus, W. in Measuring the Gains From Medical Research: An Economic Approach (eds Murphy, K. M & Topel, R. H.) 9–40 (Chicago University Press, Chicago, 2003).

    Book  Google Scholar 

  27. Calfee, J. E. Medicines' golden age. The American March/April, 41–52 (2007).

  28. Philipson, T. J. & Jena, A. B. Who Benefits From New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs. National Bureau of Economic Research (NBER) Working Paper No. 11810. NBER web site [online], (2005).

    Google Scholar 

  29. Nordhaus, W. Schumpeterian Profits in the American Economy: Theory and Measurement. National Bureau of Economic Research (NBER) Working Paper No. 10433. NBER web site [online], (2004).

    Google Scholar 

  30. Grabowski, H. G. & Wang Y. R. The quantity and quality of worldwide new drug introductions 1992–2003. Health Aff. 25, 452–460 (2006).

    Article  Google Scholar 

  31. Smith, I. et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised control trial. Lancet 369, 29–36 (2007).

    Article  CAS  Google Scholar 

  32. ASCOG. A Phase III randomized double-blind study of adjuvant imatinib mesylate versus placebo in patients following the resection of primary gastrointestinal stromal tumor. Clin. Adv. Hematol. Oncol. 2, 310 (2004).

  33. Weaver, A. L. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology 43 (Suppl. 1), iii17–iii23 (2004).

    PubMed  Google Scholar 

  34. The Pharmaceutical Research and Manufacturers of America (PhRMA). Medicines in Development. Biotechnology 2006. PhRMA web site [online], (2006).

  35. Calfee, J. E. & DuPre, E. The emerging market dynamics of targeted therapeutics. Health Aff. 25, 1302–1308 (2006).

    Article  Google Scholar 

  36. Flanagan, M. Avastin's progression. BioCentury 14, A1–A5 (2006).

    Google Scholar 

  37. Berndt, E. R., Cockburn, I. M. & Grepin, K. A. The impact of incremental innovation in biopharmaceuticals: drug utilization in original and supplemental indications. PharmacoEconomics 24 (Suppl. 2), 67–86 (2006).

    Google Scholar 

  38. Grabowski, H. G. & Vernon, J. M. Returns to R&D on new drug introductions in the 1980s. J. Health Econ. 13, 383–406 (1994).

    Article  CAS  Google Scholar 

  39. Grabowski, H. G & Vernon, J. M. Effective patent life in pharmaceuticals. Int. J. Technol. Manag. 19, 98–120 (2000).

    Article  Google Scholar 

  40. Grabowski, H. G., Vernon, J. M. & DiMasi, J. A. Returns on research and development for 1990s new drug introductions. PharmacoEconomics 20 (Suppl. 3), 11–29 (2002).

    Article  Google Scholar 

  41. Grabowski, H. G. & Kyle, M. Generic competition and market exclusivity periods in pharmaceuticals. Manag. Decis. Econ. 28, 491–502 (2007).

    Article  Google Scholar 

  42. Danzon, P., Nicholson, S. & Sousa-Pereira, N. Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances. J. Health Econ. 24, 317–339 (2005).

    Article  Google Scholar 

  43. Danzon, P., Epstein, A. & Nicholson, S. Mergers and acquisitions in the pharmaceutical and biotech industries. Manag. Decis. Econ. 28, 307–328 (2007).

    Article  Google Scholar 

  44. Centers for Medicare and Medicaid Services (CMMS). Health Care Industry Market Update: Pharmaceuticals, 10 January 2003. CMMS web site [online], (2003).

  45. Woodcock, J. “Follow-on Protein Products” Statement before the Committee on Oversight and Government Reform, U. S. House of Representatives, 26 March 2007. FDA web site [online], (2007).

    Google Scholar 

  46. Morrison, A. J. Biosimilars in the United States: a brief look at where we are and the road ahead. Biotech. Law Rep. 26, 463–468 (2007).

    Article  Google Scholar 

  47. US Federal Trade Commission (FTC). Generic Drug Entry Prior to Patent Expiration: An FTC Study. FTC web site [online], (2002).

  48. US Food and Drug Administration (FDA), Center for Drug Evaluation and Research. From Test Tube to Patient: Improving Health Through Human Drugs. FDA web site [online], (1999).

  49. DiMasi, J. A., Hansen, R. N. & Grabowski, H. G. R&D costs and returns by therapeutic category. Drug Inf. J. 38, 211–223 (2004).

    Article  Google Scholar 

  50. Adams, C. P. & Brantner, V. W. Estimating the cost of new drug development: is it really $802 million? Health Aff. 25, 420–428 (2006).

    Article  Google Scholar 

  51. Molowa, D. T. The State of Biologics Manufacturing. JP Morgan Securities, Equity Research Healthcare Research Note. 16 February (2001).

  52. Crary, C. D. Impact of KSR vs Teleflex on the Pharmaceutical Industry. Litigation Notes C. D. Crary web site [online], (2007).

    Google Scholar 

  53. Long, D. 2007 US Strategic Management Review: Trends, Issues, Outlook. Presentation to the 8th Institute for International Reasearch (IIR) Annual Generic Drugs Summit. Washington, DC, September 17–19. IIR web site [online], (2007).

    Google Scholar 

  54. Ahlstrom, A., King, R., Brown, R., Glaudemans, J., & Mendelson, D. Modeling Federal Cost Savings from Follow-on Biologics. Avalere Health web site [online], (2007).

    Google Scholar 

  55. Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nature Rev. Cancer 2, 795–803 (2002).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported in part by grants from the Pharmaceutical Research and Manufacturers of America, and the Duke University Program in Pharmaceuticals and Health Economics. The design, analysis and composition of the manuscript were conducted independently by me, and I am responsible for any errors. Early versions of this paper were presented at various forums, including the National Academy of Sciences Committee on Science Technology and Law, the Congressional Budget Office, the American Enterprise Institute, the Duke Clinical Research Institute, and the National Consumers League. I wish to thank G. Long and D. Ridley in particular for helpful comments.

Author information

Authors and Affiliations

  1. Henry Grabowski is at the Department of Economics, CB 90097, Duke University, Durham, North Carolina 27708, USA. grabow@econ.duke.edu,

    Henry Grabowski

Authors
  1. Henry Grabowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

H.G. is Director of the Program in Pharmaceuticals and Health Economics, which receives funding support from foundations, health-sector companies and government agencies.

Related links

Related links

DATABASES

The Library of Congress THOMAS

H.R. 1038

H.R. 1956

H.R. 5629

S. 1695

S. 623

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Grabowski, H. Follow-on biologics: data exclusivity and the balance between innovation and competition. Nat Rev Drug Discov 7, 479–488 (2008). https://doi.org/10.1038/nrd2532

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2532

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing